Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives $7.40 Average Price Target from Analysts

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) has received a consensus rating of “Moderate Buy” from the five analysts that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $7.40.

A number of research analysts have recently commented on the stock. Stephens restated an “overweight” rating and issued a $5.00 price target on shares of Actinium Pharmaceuticals in a report on Tuesday, November 19th. HC Wainwright restated a “buy” rating and issued a $4.00 price target on shares of Actinium Pharmaceuticals in a report on Tuesday, March 11th.

Actinium Pharmaceuticals Trading Up 2.5 %

NYSE ATNM opened at $1.23 on Tuesday. The company’s 50-day moving average price is $1.21 and its 200-day moving average price is $1.47. The stock has a market cap of $38.37 million, a PE ratio of -0.88 and a beta of 0.10. Actinium Pharmaceuticals has a 12 month low of $1.03 and a 12 month high of $10.24.

Institutional Trading of Actinium Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the business. Vontobel Holding Ltd. purchased a new stake in shares of Actinium Pharmaceuticals during the fourth quarter valued at about $32,000. Sei Investments Co. purchased a new stake in shares of Actinium Pharmaceuticals during the fourth quarter valued at about $62,000. Barclays PLC lifted its position in shares of Actinium Pharmaceuticals by 323.0% during the third quarter. Barclays PLC now owns 42,935 shares of the company’s stock valued at $81,000 after buying an additional 32,784 shares during the last quarter. Bank of America Corp DE lifted its position in shares of Actinium Pharmaceuticals by 76.6% during the fourth quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock valued at $99,000 after buying an additional 34,176 shares during the last quarter. Finally, Wellington Management Group LLP purchased a new stake in shares of Actinium Pharmaceuticals during the third quarter valued at about $112,000. 27.50% of the stock is owned by hedge funds and other institutional investors.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).